Immune Checkpoint Inhibitors
First-line nivolumab plus ipilimumab was associated with better overall survival and progression-free survival than dual targeted therapy. Nivolumab blocks PD-1 and restores effector T-cell function. Ipilimumab blocks CTLA-4 to enhance T-c…
1 sources - 5 claims
First-line nivolumab plus ipilimumab was associated with better overall survival and progression-free survival than dual targeted therapy. Nivolumab blocks PD-1 and restores effector T-cell function. Ipilimumab blocks CTLA-4 to enhance T-cell priming and proliferation. ICI therapy works by blocking inhibitory pathways that tumours use to evade immune detection. ICI causes a higher burden of severe treatment-related toxicity than dual targeted therapy.